|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In view of the specific expression pattern and immunogenicity in cancer patients, HOM-MEL-40 holds promise as a target for immune interventions in a considerable population of patients with HOM-MEL-40-positive tumors.
|
8840996 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The SYT-SSX1 and SYT-SSX2 fusion transcripts were detected in 29 (64 percent) and 16 (36 percent) of the tumors, respectively.
|
9428816 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Molecular detection of the SYT-SSX chimeric RNA should allow the reclassification of difficult cases in which the morphologic features overlap different entities or in which tumor nosology is still evolving.
|
9556426 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We now report the analysis of the expression of all 5 SSX genes in 325 specimens of human neoplasms from various histological origins, using reverse transcription polymerase chain reaction (RT-PCR).
|
9639388 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This has important implications in understanding the mechanism by which the SYT-SSX fusion protein could contribute to neoplasia.
|
9788446 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of 23 SYT-SSX-positive monophasic tumors, 16 tumors had an SYT-SSX1 fusion transcript.
|
9846971 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SYT-SSX fusion transcripts were examined by reverse transcriptase polymerase chain reaction using tumor RNA extracted from frozen or paraffin-embedded tissue.
|
10718206 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These data suggested that SYT-SSX fusion type is associated with tumor cell proliferative activity and prognosis of patients who have SS.
|
10824918 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of an SYT-SSX gene fusion resulting from the t(X;18) characteristic of synovial sarcoma was demonstrated by reverse transcriptase polymerase chain reaction in three of three tumors in which adequate RNA could be obtained from paraffin blocks.
|
10935649 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SYT-SSX gene fusion transcripts were detected in the SS tumor category only (100% specificity), including 100% of the biphasic SS and 86% of monophasic spindle/round cell SS.
|
11172303 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of the t(X;18) with SSX2 involvement definitively characterizes this tumour as a variant of synovial sarcoma.
|
11207827 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This case report indicates that synovial sarcoma should be taken into account for the differential diagnosis of renal spindle cell tumors and the molecular assay detecting the SYT-SSX fusion transcripts is useful for the final diagnosis of synovial sarcoma arising in an unusual location.
|
11422798 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combining cytogenetic complexity and transcript data, we found that the subgroup of patients with tumors showing simple karyotypes and SYT/SSX2 fusion had the best clinical outcome (2/8 patients developed metastases), and those with tumors showing complex karyotypes together with SYT/SSX1 fusion the worst (6/7 patients developed metastases).
|
11433527 |
2001 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Overall survival was significantly better among SYT-SSX2 cases (P = 0.03), among cases localized at diagnosis (P < 0.0001), and among patients with primary tumors < 5 cm in greatest dimension (P = 0.01).
|
11782370 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Five tumor samples (15.6%) were positive by RT-PCR using SSX consensus primers and direct sequencing of the RT-PCR products showed that 4 of 5 expressed more than 1 SSX family member.
|
12094374 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RT-PCR was used to amplify the SYT-SSX fusion transcripts using archival formalin-fixed paraffin-embedded tumor specimens from a series of 37 synovial sarcoma cases.
|
12150740 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that SYT-SSX may influence the cell cycle machinery, and that the more aggressive phenotype of the SYT-SSX1 variant is due to an accelerated tumour cell proliferation.
|
12173050 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sensitivity experiments showed SSX-2 detection was one tumor cell in 10(6) normal cells, and one in 10(4) for SSX-4.
|
12521124 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because SS18/SSX fusions do not seem to occur in other tumor types, and because synovial sarcomas may sometimes be difficult to distinguish from other spindle cell tumors, molecular genetic analysis has become established as an important diagnostic tool.
|
12696068 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The absence of detectable response in healthy donors and other patients suggests that SSX-2-specific CD4(+) T cells in the responder patient had been previously expanded in vivo in response to the autologous tumor.
|
15153546 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These circumstances accentuate the impact of SS18/SSX analysis in diagnosis of renal hemangiopericytoma-like tumors.
|
15163009 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The SS18-SSX fusions do not seem to occur in other tumor types, and it has been shown that in synovial sarcoma a clear correlation exists between the type of fusion gene and histologic subtype and, more importantly, clinical outcome.
|
15208645 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ratio of SYT-SSX1:SYT-SSX2 fusion was 7:18 for monophasic and 2:7 for biphasic tumors in the Slovenian group.
|
15350633 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No correlation was found between CD4+ T-cell responses against p45-59 reactivity and anti-SSX2 antibody titers in the serum of patients, suggesting that CD4+ and B-cell responses are regulated independently. p45-59 holds promise as a broadly applicable peptide vaccine for patients with SSX2-positive neoplasms.
|
15382048 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the SYT/SSX2 fusion is usually associated with the monophasic disease pattern, the SYT/SSX1 fusion is present in tumors with biphasic or monophasic patterns.
|
15641030 |
2005 |